Alzheimer’s drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
Related Articles
-
CDC expected to alert doctors about fake Botox
The Centers for Disease Control and Prevention is poised to alert doctors nationwide about fake Botox injections that have...
-
Study reports sugary drinks may double risk of colon cancer in younger women
IE 11 is not supported. For an optimal experience visit our site on another browser. 05:30 Share this –...
-
A measles crisis decades in the making: How RFK Jr. helped drive America to this moment
A child in the United States has died from measles. Just two weeks after his confirmation as Health and...
-
Judge’s abortion pill decision embraces extreme language and ideology of anti-abortion movement, experts say
Judge Kacsmaryk’s decision to pause the FDA’s approval of the abortion pill mifepristone reads as ideological and extreme, according...
-
Bird flu virus found in pasteurized milk, though officials maintain supply is safe
The Food and Drug Administration said Tuesday that fragments of the bird flu virus had been detected in some...
-
‘Horrific’: 2 unvaccinated Covid patients require lung transplant, partial lung removal
The families of two unvaccinated men who underwent major lung surgery after they contracted the coronavirus are encouraging others...
-
New York doctor says he’ll continue providing transition care despite Trump executive order
A New York City doctor said he will continue providing gender-affirming treatments to his patients younger than 19 despite...
-
The problem with pulse oximeters your doctor probably doesn’t know about
The doctors and nurses didn’t believe Tomisa Starr was having trouble breathing. Two years ago, Starr, 61, of Sacramento,...
Recent Comments